Institut Curie at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Institut Curie brings 3 presentations to ENA 2026 in Barcelona. Its posters centre on antibody-drug conjugates in breast cancer and on drug resistance in patient-derived xenografts. Highlights are INA03, an MMAE-based ADC against the transferrin receptor CD71 that is active in models resistant to TOP1-ADCs, and a phenotype that predicts trastuzumab deruxtecan sensitivity regardless of HER2 expression.

Organization	ENA 2026 Attendance
Institut Curie Paris, France
curie.fr Cancer centres & hospitals Cancer centre combining a research centre and hospital, with translational work on patient-derived models.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates INA03, a MMAE-based ADC targeting the transferrin receptor CD71, demonstrates potent antitumor activity in breast cancer PDX models resistant to TOP1-ADCs ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Unfolded Protein Response as a Driver of Carboplatin-Paclitaxel Resistance in Ovarian Cancer Patient-Derived Xenografts Targeted agents

Organization

ENA 2026 Attendance

Institut Curie

Paris, France

curie.fr

Cancer centres & hospitals

Cancer centre combining a research centre and hospital, with translational work on patient-derived models.

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm

Part of Poster session: Antibody-drug conjugates

INA03, a MMAE-based ADC targeting the transferrin receptor CD71, demonstrates potent antitumor activity in breast cancer PDX models resistant to TOP1-ADCs

ADCs & radioligands